REMSIMA 120 mg, solution for injection in a pre-filled pen pen, 1 ml
Active ingredients: Infliximab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionpen, 1 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- REMSIMA 120 mg, solution injectable en stylo prérempli
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 stylo prérempli en verre de 1 mL avec 2 tampons alcoolisés
- Marketing authorisation holder
- CELLTRION HEALTHCARE HUNGARY (HONGRIE)
- Reimbursement according to BDPM
- 65%
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- Polyarthrite rhumatoïde, en association au méthotrexate<br>- Maladie de Crohn<br>- Rectocolite hémorragique<br>- Spondylarthrite ankylosante<br>- Rhumatisme psoriasique en plaques chronique sévère ; JOURNAL OFFICIEL ; 02/02/21
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 2 Feb 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64428871CIP73019935CIP133400930199350Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| INFLIXIMABsolution | 120 mg · un stylo prérempli de 1 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.